Acute sunburn
Sunburn is an acute cutaneous inflammatory reaction that follows excessive exposure of the skin to ultraviolet radiation (UVR). UVR exposure can come from a variety of sources, including sun, tanning beds, phototherapy lamps, and arc lamps.1 Long-term adverse health effects of repeated exposure to UVR are well described but are beyond the scope of this article. Sunburn is generally classified as a superficial or first-degree burn
Exposure to solar radiation has the beneficial effects of stimulating the cutaneous synthesis of vitamin D and providing radiant warmth. Unfortunately, when the skin is subjected to excessive radiation in the ultraviolet range, deleterious effects may occur. The most conspicuous is acute sunburn or solar erythema.2
Initially, UVR causes vasodilation of cutaneous blood vessels, resulting in the characteristic erythema. Within an hour of UVR exposure, mast cells release preformed mediators including histamine, serotonin, and tumor necrosis factor, leading to prostaglandin and leukotriene synthesis.2,3 Cytokine release additionally contributes to the inflammatory reaction, leading to an infiltrate of neutrophils and T lymphocytes.4 Within 2 hours after UV exposure, damage to epidermal skin cells is seen. Both epidermal keratinocytes (“sunburn cells”) and Langerhans cells undergo apoptotic changes as a consequence of UVR-induced DNA damage.5,6 Erythema usually occurs 3-
Less intense or shorter-duration exposure to UVR results in an increase in skin pigmentation, known as tanning, which provides some protection against further UVR-induced damage.8 The increased skin pigmentation occurs in 2 phases: (1) immediate pigment darkening and (2) delayed tanning. Immediate pigment darkening occurs during exposure to UVR and results from alteration of existing melanin (oxidation, redistribution). It may fade rapidly or persist for several days. Delayed tanning results from increased synthesis of epidermal melanin and requires a longer period of time to become visible (24-72 h). With repeated exposure to UVR, the skin thickens, primarily due to epidermal hyperplasia with thickening of the stratum corneum. UVR exposure also suppresses cutaneous cell-mediated immunity, contributing to nonmelanoma skin cancer and infectious disease development
4 hours after exposure, with peak levels at 24 hours
History and symptoms for sunburn may include the following:
Subacute sunburn of shoulder with peeling in a 21-year-old male.
Sunburn is caused by excessive exposure of the skin to UVR. The ultraviolet spectrum can be divided into ultraviolet A-I (UVA-I), 340-400 nm; ultraviolet A-II (UVA-II), 320-340 nm, ultraviolet B (UVB), 290-320 nm; and ultraviolet C (UVC), 200-290 nm.1 Solar UVR of wavelengths shorter than 290 nm are filtered out or absorbed in the outer atmosphere and are not encountered at sea level.1 Shorter wavelength UVB rays are much more effective at inducing erythema than UVA rays and, therefore, are the principal cause of sunburn.1 However, UVA comprises the majority of UVR reaching the surface of the earth (about 95-98% at midday) and, therefore, accounts for a significant percentage of the immediate and long-term cutaneous effects of UVR.1
The minimal single dose of UVR (energy per unit area) required to produce erythema after 24 hours at an exposed site is known as the minimal erythema dose (MED). This dose differs by skin type.2
Multiple factors influence UVR-induced erythema; these are listed below.
The symptoms of minor sunburn can be relieved to some extent with cool compresses or a cool bath. Administration of nonprescription analgesics and NSAIDs for the treatment of pain and inflammation is recommended.
These medications can reduce the pain and inflammation associated with sunburn.
For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis.
500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d
<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d
Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency
B – Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
D – Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug
Used for the treatment of mild to moderate pain. Also acts on the hypothalamus heat-regulating center to reduce fever.
650 mg PO bid/qid; not to exceed 4 g/d in equally divided doses
10-15 mg/kg/dose PO q4-6h; not to exceed 60-80 mg/kg/d
Effects may decrease with antacids and urinary alkalinizers; corticosteroids decrease salicylate serum levels; additive hypoprothrombinemic effects and increased bleeding time may occur with coadministration of anticoagulants; may antagonize uricosuric effects of probenecid and increase toxicity of phenytoin and valproic acid; doses >2 g/d may potentiate glucose-lowering effect of sulfonylurea drugs
Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma; children (<16 y) with flu (because of association with Reye syndrome)
C – Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
D – Fetal risk shown in humans; use only if benefits outweigh risk to fetus
May cause transient decrease in renal function and aggravate chronic kidney disease; avoid use in patients with severe anemia, in those with history of blood coagulation defects, or in those taking anticoagulants
Usually the DOC for the treatment of mild to moderate pain, if no contraindications are present.
200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d
30-70 mg/kg/d PO tid/qid
Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding
B – Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
D – Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy
These agents are used to decrease the pain associated with sunburn.
DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, in those with upper GI disease, or in those who are taking oral anticoagulants.
Effective in relieving mild to moderate acute pain; however, has no peripheral anti-inflammatory effects. May be preferred in elderly patients because of fewer GI and renal side effects.
325-650 mg PO/PR q4-6h or 1000 mg tid/qid; not to exceed 4 g/d
<12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d
>12 years: 325-650 mg PO q4h; not to exceed 4 g/d
Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity
Documented hypersensitivity; known G-6-PD deficiency
B – Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Hepatotoxicity possible in chronic alcoholics following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; contained in many OTC products and combined use with these products may result in toxicity due to cumulative doses exceeding recommended maximum dose
Because they modify the body’s immune response, corticosteroids are thought to decrease erythema and shorten the course of sunburn.
May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
40-60 mg PO qd
1 mg/kg PO qd